{"id":2384,"date":"2023-07-19T07:33:32","date_gmt":"2023-07-19T07:33:32","guid":{"rendered":"https:\/\/dianhuaminglu.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/"},"modified":"2023-07-25T07:45:20","modified_gmt":"2023-07-25T07:45:20","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf","status":"publish","type":"post","link":"https:\/\/dianhuaminglu.com\/zh-hant\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/","title":{"rendered":"\u541b\u5be6\u751f\u7269\u7279\u745e\u666e\u5229\u55ae\u6297\u7528\u65bc\u5ee3\u6cdb\u671f\u5c0f\u7d30\u80de\u80ba\u764c\u4e00\u7dda\u6cbb\u7642\u7684\u65b0\u9069\u61c9\u75c7\u4e0a\u5e02\u7533\u8acb\u7372\u53d7\u7406"},"content":{"rendered":"\n
\u5317\u4eac\u6642\u95932023\u5e747\u670819\u65e5\uff0c\u541b\u5be6\u751f\u7269\uff081877.HK\uff0c688180.SH\uff09\u5ba3\u4f48\uff0c\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u5df2\u53d7\u7406\u516c\u53f8\u81ea\u4e3b\u7814\u767c\u7684\u6297PD-1\u55ae\u6297\u85e5\u7269\u7279\u745e\u666e\u5229\u55ae\u6297\u806f\u5408\u4f9d\u8a17\u6cca\u82f7\u548c\u9251\u985e\u7528\u65bc\u5ee3\u6cdb\u671f\u5c0f\u7d30\u80de\u80ba\u764c\u4e00\u7dda\u6cbb\u7642\u7684\u65b0\u9069\u61c9\u75c7\u4e0a\u5e02\u7533\u8acb\u3002\u9019\u662f\u7279\u745e\u666e\u5229\u55ae\u6297\u5728\u4e2d\u570b\u905e\u4ea4\u7684\u7b2c\u5341\u9805\u4e0a\u5e02\u7533\u8acb\u3002<\/p>\n\n\n\n
\u80ba\u764c\u662f\u76ee\u524d\u6211\u570b\u767c\u75c5\u7387\u548c\u6b7b\u4ea1\u7387\u5747\u6392\u540d\u9996\u4f4d\u7684\u60e1\u6027\u816b\u76241<\/sup>\u3002\u5c0f\u7d30\u80de\u80ba\u764c\uff08SCLC\uff09\u662f\u80ba\u764c\u4e2d\u4fb5\u8972\u6027\u6700\u5f37\u7684\u4e9e\u578b2<\/sup>\uff0c\u7d04\u5360\u6240\u6709\u80ba\u764c\u75c5\u4f8b\u768415%-20%3<\/sup>\uff0c\u5177\u6709\u9032\u5c55\u8fc5\u901f\u3001\u65e9\u671f\u8f49\u79fb\u3001\u9810\u5f8c\u5dee\u7b49\u7279\u9ede4<\/sup>\u3002SCLC\u5206\u70ba\u5c40\u9650\u671f\uff08LS-SCLC\uff09\u548c\u5ee3\u6cdb\u671f\uff08ES-SCLC\uff09\u3002\u5c0d\u65bcLS-SCLC\u60a3\u8005\uff0c\u901a\u904e\u6a19\u6e96\u5316\u7642\u548c\u653e\u7642\uff0c\u76ee\u524d\u5df2\u53ef\u9054\u5230\u7d0490%\u7684\u5ba2\u89c0\u7de9\u89e3\u7387\u548c\u7d0425%\u76845\u5e74\u751f\u5b58\u73875,6<\/sup>\u3002\u7136\u800c\uff0c\u5927\u90e8\u5206\u60a3\u8005\u5728\u5c31\u8a3a\u6642\uff0c\u5df2\u88ab\u8a3a\u65b7\u70baES-SCLC\uff0c\u4e2d\u4f4d\u751f\u5b58\u671f\u4e0d\u8db31\u5e747<\/sup>\uff0c2\u5e74\u751f\u5b58\u7387\u4e0d\u523010%8<\/sup>\uff0c\u4ecd\u662f\u81e8\u5e8a\u672a\u89e3\u6c7a\u7684\u4e00\u5927\u96e3\u984c\u3002<\/p>\n\n\n\n \u672c\u6b21\u65b0\u9069\u61c9\u75c7\u7684\u4e0a\u5e02\u7533\u8acb\u4e3b\u8981\u57fa\u65bcEXTENTORCH\u7814\u7a76\uff08NCT04012606\uff09\uff0c\u662f\u4e00\u9805\u96a8\u6a5f\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7684III\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u7531\u5409\u6797\u7701\u816b\u7624\u91ab\u9662\u7a0b\u7a4e\u6559\u6388\u64d4\u4efb\u4e3b\u8981\u7814\u7a76\u8005\uff0c\u5728\u5168\u570b51\u5bb6\u81e8\u5e8a\u4e2d\u5fc3\u806f\u5408\u958b\u5c55\u3002\u8a72\u7814\u7a76\u65e8\u5728\u6bd4\u8f03\u7279\u745e\u666e\u5229\u55ae\u6297\u6216\u5b89\u6170\u5291\u806f\u5408\u4f9d\u8a17\u6cca\u82f7\u53ca\u9251\u985e\u5728\u4e00\u7dda\u6cbb\u7642ES-SCLC\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002<\/p>\n\n\n\n 2023\u5e745\u6708\uff0cEXTENTORCH\u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u9054\u5230\u65b9\u6848\u9810\u8a2d\u7684\u512a\u6548\u908a\u754c\uff0c\u7279\u745e\u666e\u5229\u55ae\u6297\u7531\u6b64\u6210\u70ba\u5168\u7403\u9996\u500b\u5728ES-SCLC\u4e00\u7dda\u6cbb\u7642III\u671f\u7814\u7a76\u4e2d\u9054\u6210\u7e3d\u751f\u5b58\u671f\uff08OS\uff09\u548c\u7121\u9032\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u96d9\u91cd\u4e3b\u8981\u7d42\u9ede\u7684PD-1\u6291\u5236\u5291\u3002<\/p>\n\n\n\n \u7d50\u679c\u986f\u793a\uff0c\u76f8\u6bd4\u55ae\u7d14\u5316\u7642\uff0c\u7279\u745e\u666e\u5229\u55ae\u6297\u806f\u5408\u5316\u7642\u4e00\u7dda\u6cbb\u7642ES-SCLC\u53ef\u986f\u8457\u5ef6\u9577\u60a3\u8005\u7684PFS\u548cOS\u3002\u7279\u745e\u666e\u5229\u55ae\u6297\u5b89\u5168\u6027\u8cc7\u6599\u8207\u65e2\u5f80\u7814\u7a76\u76f8\u4f3c\uff0c\u672a\u767c\u73fe\u65b0\u7684\u5b89\u5168\u6027\u4fe1\u865f\u3002EXTENTORCH\u7814\u7a76\u7684\u8a73\u7d30\u8cc7\u6599\u5c07\u5728\u8fd1\u671f\u7684\u570b\u969b\u5b78\u8853\u5927\u6703\u4e0a\u516c\u4f48\u3002<\/p>\n\n\n\n \u5409\u6797\u7701\u816b\u7624\u91ab\u9662\u7a0b\u7a4e\u6559\u6388<\/strong>\u8868\u793a\uff1a\u201cSCLC\u65e9\u671f\u75c7\u72c0\u4e0d\u660e\u986f\uff0c\u4e14\u816b\u7624\u589e\u6b96\u901f\u5ea6\u5feb\u3001\u60e1\u6027\u7a0b\u5ea6\u9ad8\uff0c\u56e0\u6b64\u5927\u90e8\u5206\u60a3\u8005\u521d\u8a3a\u6642\u5df2\u767c\u5c55\u70ba\u665a\u671f\u751a\u81f3\u662f\u5168\u8eab\u8f49\u79fb\uff0c\u82e5\u78ba\u8a3a\u70baES-SCLC\uff0c\u60a3\u8005\u7684\u751f\u5b58\u6642\u9593\u50c51\u5e74\u5de6\u53f3\u3002EXTENTORCH\u6210\u529f\u8b49\u5be6\u4e86\u5728\u5316\u7642\u57fa\u790e\u4e0a\u806f\u7528\u7279\u745e\u666e\u5229\u55ae\u6297\u4e00\u7dda\u6cbb\u7642ES-SCLC\u53ef\u986f\u8457\u6539\u5584\u60a3\u8005\u7684PFS\u548cOS\uff0c\u53ef\u80fd\u70baES-SCLC\u60a3\u8005\u63d0\u4f9b\u66f4\u8c50\u5bcc\u3001\u66f4\u6709\u6548\u7684\u6cbb\u7642\u9078\u64c7\u3002\u201c<\/strong><\/p>\n\n\n\n \u541b\u5be6\u751f\u7269\u5168\u7403\u7814\u767c\u7e3d\u88c1\u9112\u5efa\u8ecd\u535a\u58eb<\/strong>\u8868\u793a\uff1a\u201c\u5f88\u9ad8\u8208\u5728\u4eca\u5929\u898b\u8b49\u4e86\u7279\u745e\u666e\u5229\u55ae\u6297\u7b2c10\u9805\u9069\u61c9\u75c7\u7684\u6210\u529f\u7533\u5831\u3002\u81ea2015\u5e74\u5e95\u7372\u51c6\u9032\u5165\u81e8\u5e8a\u4ee5\u4f86\uff0c\u7279\u745e\u666e\u5229\u55ae\u6297\u7784\u6e96\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u816b\u7624\u60a3\u8005\u7684\u672a\u76e1\u4e4b\u9700\uff0c\u5df2\u9678\u7e8c\u958b\u5c55\u4e86\u8d85\u904e40\u9805\u8a3b\u518a\u81e8\u5e8a\u8a66\u9a57\uff0c\u4e26\u5728\u4e0d\u540c\u7624\u7a2e\u4e2d\u8868\u73fe\u51fa\u7a69\u5b9a\u3001\u5f37\u5927\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002\u5176\u4e2d\u50c5\u80ba\u764c\u9818\u57df\uff0c\u7279\u745e\u666e\u5229\u55ae\u6297\u5df2\u67093\u9805\u5927\u578bIII\u671f\u81e8\u5e8a\u7814\u7a76\u53d6\u5f97\u6210\u529f\uff0c\u8986\u84cb\u4e86\u4e0d\u540c\u4e9e\u578b\u548c\u75c5\u7a0b\u968e\u6bb5\u3002\u6211\u5011\u5c07\u52aa\u529b\u63a8\u9032\u76f8\u95dc\u9069\u61c9\u75c7\u7684\u4e0a\u5e02\u7533\u8acb\u5de5\u4f5c\uff0c\u8b93\u66f4\u591a\u816b\u7624\u60a3\u8005\u80fd\u5920\u53d7\u76ca\u4e8e\u6211\u5011\u7684\u5275\u65b0\u7642\u6cd5\uff01\u201c<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n\u3010\u53c3\u8003\u6587\u737b\u3011<\/h5>\n\n\n\n
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4.<\/h5>\n\n\n\n
2. \u5f35\u723d\u7b49.\u5c0f\u7d30\u80de\u80ba\u764c\u500b\u9ad4\u5316\u6cbb\u7642\u9032\u5c55[J].\u4e2d\u570b\u816b\u7624\u81e8\u5e8a,2017,44(12):571-576.<\/h5>\n\n\n\n
3. Gaspar LE, et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer. 2012 Mar;13(2):115-22.<\/h5>\n\n\n\n
4. Pesch B, et al. Cigarette smoking and lung cancer–relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 2012 Sep 1;131(5):1210-9.<\/h5>\n\n\n\n
5. Kalemkerian GP. Small Cell Lung Cancer. Semin Respir Crit Care Med. 2016 Oct;37(5):783-796.<\/h5>\n\n\n\n
6. Stinchcombe TE, et al. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist. 2010;15(2):187-95.<\/h5>\n\n\n\n
7. Lally BE, et al. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist. 2007 Sep;12(9):1096-104.<\/h5>\n\n\n\n
8. Socinski MA, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009 Oct 1;27(28):4787-92.<\/h5>\n\n\n\n
1. <\/em>\u672c\u6750\u6599\u65e8\u5728\u50b3\u905e\u524d\u6cbf\u8cc7\u8a0a\uff0c\u7121\u610f\u5411\u60a8\u505a\u4efb\u4f55\u7522\u54c1\u7684\u63a8\u5ee3\uff0c\u4e0d\u4f5c\u70ba\u81e8\u5e8a\u7528\u85e5\u6307\u5c0e\u3002<\/em><\/em><\/h6>\n\n\n\n
2. <\/em>\u82e5\u60a8\u60f3\u77ad\u89e3\u5177\u9ad4\u75be\u75c5\u8a3a\u7642\u8cc7\u8a0a\uff0c\u8acb\u9075\u5f9e\u91ab\u7642\u885b\u751f\u5c08\u696d\u4eba\u58eb\u7684\u610f\u898b\u8207\u6307\u5c0e\u3002<\/em><\/em><\/h6>\n\n\n\n